MML and PHTA Join Forces at Birmingham Health Innovation Campus to Boost MedTech Innovation

The MedTech sector is evolving rapidly, and collaboration plays a key role in turning ideas into real-world health solutions. Starting June 1, 2026, MedTech Makers Lab (MML) will move into the Precision Health Technologies Accelerator (PHTA) at the Birmingham Health Innovation Campus (BHIC). This partnership, alongside the University of Birmingham, aims to create a vibrant hub for MedTech innovation, connecting entrepreneurs, clinicians, investors, and researchers in one place.

A New Home for MedTech Makers Lab

MML’s relocation to BHIC marks a significant step in its mission to support MedTech startups and scale-ups. The campus is designed to bring together diverse stakeholders in life sciences and healthcare innovation. Its proximity to the University of Birmingham and NHS clinical research infrastructure offers unique advantages for companies developing new health technologies.

This move means MML can offer its community better access to clinical trials, regulatory guidance, and commercialisation pathways. It also strengthens ties with academic research and healthcare providers, accelerating the journey from concept to patient impact.

What the Partnership Means for MedTech Innovation

The collaboration between MML and PHTA is formalized through a Memorandum of Understanding (MoU). This agreement sets out a framework for joint activities that will benefit MedTech innovators across the UK and Europe. Key areas of focus include:

• Innovation workshops to share knowledge and develop new ideas

• Engagement events connecting founders with investors and healthcare experts

• Support for international companies looking to expand into the UK market

• Pathways for startups to access clinical, regulatory, and commercial resources

  
  

By working together, MML and PHTA aim to build a stronger ecosystem that supports every stage of MedTech development.

Why Birmingham Health Innovation Campus Is the Ideal Location

BHIC is one of the UK’s most ambitious life sciences developments. It brings together academia, healthcare, industry, entrepreneurs, and investors in a collaborative environment. The campus is purpose-built to speed up the development and validation of health technologies.

Its location next to the University of Birmingham means companies can tap into cutting-edge research and a skilled talent pool. Close links with NHS facilities provide opportunities for clinical testing and real-world feedback. This combination creates a fertile ground for innovation that can quickly move from lab to market.

Building a Pan-European and International MedTech Platform

MML’s vision extends beyond the UK. The partnership with PHTA supports building a pan-European and international platform for MedTech innovation. This platform connects founders, clinicians, investors, regulators, and healthcare systems across borders.

Such a network helps companies navigate complex regulatory environments and access new markets. It also encourages collaboration on shared challenges like digital health, medical devices, and diagnostics. By positioning Birmingham as a gateway, the partnership opens doors for global MedTech growth and deployment.

Practical Benefits for MedTech Startups and Scale-ups

Startups and scale-ups joining the MML-PHTA ecosystem can expect several practical benefits:

• Access to expert advice on clinical trials, regulatory approval, and market entry

• Opportunities to pitch to investors and healthcare partners

• Participation in workshops that build skills and knowledge

• Support for inward investment to grow their business in the UK

• Connections to NHS and academic research for validation and collaboration

  
  

These resources help reduce barriers and speed up the path to successful product launches.

Strengthening the UK Healthcare and Life Sciences Sector

This collaboration also benefits the broader UK healthcare and life sciences sector. By attracting international companies and fostering innovation, BHIC and its partners contribute to economic growth and improved patient outcomes.

The partnership supports the UK government’s goals to boost health technology development and adoption. It also helps create jobs and build expertise in a competitive global market.

What to Expect Next

With the MoU signed and MML’s move underway, the next steps include launching joint programs and events. Founders and investors can look forward to new opportunities for networking and collaboration. Emerging health technology companies will gain clearer pathways to clinical and commercial success.

This partnership signals a strong commitment to building a connected, supportive MedTech ecosystem in Birmingham and beyond.